SPECIAL THANKS TO DOUG BREMNER, CHRISTOPHER LANE AND HEALTHY SKEPTICISM FOR MAKING SOME OF THESE DOCUMENTS AVAILABLE
PAXIL/SEROXAT - GREATEST NUMBER OF SUICIDE ATTEMPTS
----
----
----
FOREWORD BY PAUL N. JENNER, DIRECTOR AND VICE PRESIDENT OF NEUROSCIENCE AND STRATEGIC PRODUCT DEVELOPMENT
----
SECTION 1: TOWARDS THE SECTION BILLION -- ALL SSRI'S ARE NOT THE SAME
----
SECTION 2: NEW INDICATIONS: SOCIAL ANXIETY DISORDER / SOCIAL PHOBIA
----
"PAXIL CR" PRODUCT MONOGRAPH
----
PAXIL LITIGATION DOCUMENTS
----
GSK's PAXIL.COM...STILL A WEALTH OF [DIS] INFORMATION
----
DOCUMENT RETENTION, LETTERS TO MINISTERS, LETTERS AND EMAILS ABOUT SEROXAT AND LIST OF FOI REQUESTS
----
MINUTES OF MEETING BETWEEN MHRA AND BOB FIDDAMAN
----
PRESS RELEASE: GSK INVESTIGATION CONCLUDES
----
MHRA INVESTIGATION INTO GLAXOSMITHKLINE/SEROXAT
----
GSK SEROXAT - LETTER TO GSK FROM MHRA
----
GSK SEROXAT - LETTER TO TRADE ASSOCIATIONS
----
SUMMARY OF REGULATORY ACTION
----
LETTER FROM GSK CHIEF MEDICAL OFFICER TO MHRA
----
MHRA RESPONSE TO LETTER FROM GSK CHIEF MEDICAL OFFICER
----
PAXIL STUDY 329 ALL OVER AGAIN?
Article By Bob Fiddaman
----
MARKET SENTINEL'S STAKEHOLDER ANALYSIS COMMISSIONED BY THE UK MHRA TO ASSESS PUBLIC DISCUSSION OF THE SEROXAT CONTROVERSY
----
----
GSK PAXIL CASPPER DOCUMENT
----
GLAXOSMITHKLINE PROGRAM CALLED “PSYCHNET”
----
----
----
----
SECTION 3: ISSUES MANAGEMENT: MANAGING THE DISCONTINUATION ISSUE
----
"DURATION OF TREATMENT AND DEPRESSION: RELAPSE AND RECURRENCE RATES"
----
----
----
----
----
----
----
----
----
----
----
----
----
Article By Bob Fiddaman
----
----
KILKER V GLAXOSMITHKLINE COURT TRANSCRIPTS
----
PAXIL STUDY 329: PAROXETINE vs IMIPRAMINE vs PLACEBO IN ADOLESCENTS
Fid
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
